References
Lewis U.J., Singh R.P.N., Sinha Y.N., VanderLaan W.P. Electrophoretic evidence for human prolactin. J. Clin. Endocrinol. Metab. 33: 153, 1971.
Hwuang P., Guyda H., Friesen H. A radioimmunoassay for human prolactin. Proc. Natl. Acad. Sci. USA 68: 1902, 1971.
Blackwell R.E. Diagnosis and management of prolactinomas. Fertil. Steril. 43: 5, 1985.
Grossman A., Besser G.M. Prolactinomas. Br. Med. J. 290: 182, 1985.
Frantz A.G., Kleingerg D.L., Noel G.L. Studies on prolactin in man. Recent Prog. Horm. Res. 28: 527, 1972.
Franks S., Jacobs H.S. Characterization and management of hyperprolactinemic amenorrhea. In: Crosignani P.G., Robyn C. (Eds.), Prolactin and human reproduction. Academic Press, New York, 1977, p. 245.
Boyar R.M., Kapen S., Finkelstein J.W., Parlow M., Sassin J.F., Fukushima D.K., Weitzmann E.D., Hellman L. Hypothalamic pituitary function in diverse hyperprolactinemic states. J. Clin. Invest. 53: 1588, 1974.
Malarkey W.B., Johnston J.C. Pituitary tumors and hyperprolactinemia. Arch. Intern. Med., 136: 4Q, 1976.
Malarkey W.B., Goodenow T.H., Lanese R.R. Diurnal variation of prolactin secretion differentiates pituitary tumors from primary empty sella syndrome. Am. J. Med. 69: 886, 1980.
Andersen A.N., Tabor A. PRL, TSH, GH and LH responses to metoclopramide and breast feeding in normal and hyperprolactinemic women. Acta Endocrinol. (Copenh.) 100: 177, 1982.
Van Loon G.R. A defect in catecholamine neurons in patients with prolactin-secreting pituitary adenoma. Lancet 2: 868, 1978.
Tucker H.G., Lankford H.V., Gardner D.F., Blackard W.G. Persistent defect in regulation of prolactin secretion after successful pituitary removal in women with amenorrhea-galactorrhea syndrome. J. Clin. Endocrinol. Metab. 51: 968, 1980.
Melis G.B., Paoletti A.A., Mais V., Mastropasqua N.M., Strigini F., Fruzzetti F., Guarneri G., Gambacciani M., Fioretti P. The effect of the gabaergic drug, sodium valproate, on prolactin secretion in normal and hyperprolactinemic subjects. J. Clin. Endocrinol. Metab., 54: 485, 1982.
Gonzales-Villipandio C., Szabo M., Frohman L.A. Central nervous system-mediated stimulation of prolactin secretion by Cimetidine, a histamine H2-receptor antagonist: impaired responsiveness in patients with prolactin-secreting tumors and idiopathic hyperprolactinemia. J. Clin. Endocrinol. Metab. 51: 1417, 1980.
Quigley M.E., Ishizuka B., Robert J.F., Yen S.S.C. The food-entrained prolactin and Cortisol release in late pregnancy and prolactinoma patients. J. Clin. Endocrinol. Metab. 54: 1109, 1982.
Kletzky O.A., Davajan V., Mishell D.R., Nikoloff J.T., Mims R., March C.M., Nakamura R. A sequential pituitary stimulation test in normal subjects and in patients with amenorrhea-galactorrhea with pituitary tumors. J. Clin. Endocrinol. Metab. 45: 631, 1977.
Hagen T.C., Sill A.J., Garthwaite T.L., Halverson G., Barkhowe H.I. Prolactin and growth hormone response in the amenorrhea-galactorrhea syndrome. Obstet. Gynecol. 56: 204, 1980.
Seki K., Kato K., Shima K. Absence of growth hormone response to L-dopa and bromocriptine in hyperprolactinemic women with pituitary microadenoma. J. Clin. Endocrinol. Metab. 62: 783, 1986.
Massara F., Camanni F., Belforte L., Vergnano V., Molinatti G.M. Increased Thyrotropin secretion induced by sulpiride in man. Clin. Endocrinol. (Oxf.) 9: 419, 1978.
Massara F., Camanni F., Martra M., Dolfin G.C., Muller E.E., Molinatti G.M. Reciprocal pattern of the thyrotropin and prolactin response to dopamine receptor blockade in women with physiological or pathological hyperprolactinemia. Clin. Endocrinol. (Oxf.) 18: 103, 1983.
Scanion M.F., Rodriguez-Arnao M.D., Mc Gregor A.M., Weightman D.R., Lewis M., Cook D.B, Gomez-Pan A., Hall R. Altered dopaminergic regulation of thyrotropin release in patients with prolactinomas: comparison with other tests of hypothalamic-pituitary function. Clin. Endocrinol. (Oxf.) 14: 133, 1981.
Quigley M.E., Judd S.J., Gilliland G.B., Yen S.S.C. Effects of dopamine antagonist on the release of gonadotropin and prolactin in normal women and women with hyperprolactinemic anovulation. J. Clin. Endocrinol. Metab. 48: 718, 1979.
Quigley M.E., Yen S.S.C. Evidence for increased dopaminergic inhibition of secretion of thyrotropin-releasing hormone in hyperprolactinemic patients with pituitary microadenoma. Am. Obstet. Gynecol. 137: 653, 1980.
Tolis G. Prolactin: physiology and pathology. In: Krieger D.T., Hughes J.C. (Eds.), Neuroendocrinology. Sinauer Associates Inc Sunderland Massachusetts p. 321.1980.
Bohnet H.G., Dahlen H.G. Wuttke W., Schneider H.P.G. Hyperprolactinemic anovulatory syndrome. J. Clin Endocrinol. Metab. 42: 132, 1976.
Moult P.J.A., Rees L.H., Besser G.M. Pulsatile gonadotrophin secretion in hyperprolactinemic amenorrhea and the response to bromocriptine therapy. Clin. Endocrinol. (Oxf.) 16: 153, 1982.
Buckman M.T., Peake G.T., Srivastava L. Patterns of spontaneous LH release in normal and hyperprolactinemic women. Acta Endocrinol. (Copenh.) 97: 305, 1981.
Grossman A., Moult P.J., Mc Intyre H., Evans J., Silverstone T., Rees L.H., Besser G.M. Opiate mediation of amenorrhea in hyperprolactinemia and weight-loss related amenorrhea. Clin. Endocrinol. (Oxf.) 17: 379, 1982.
Muller E.E., Camanni F., Genazzani A.R., Casanueva F., Cocchi D., Locatelli V., Massara F., Mantegazza P. Dopamino-mimetic and antagonist drugs: diagnostic and therapeutic applications in endocrine disorders. Life Sci. 29: 867, 1981.
Gennazzani A.R., Camanni F., Massara F., Picciolini F., Cocchi D., Belforte L., Muller E.E. A new pharmacological approach to the diagnosis of hyperprolactinemic states: the nomifensine test. Acta Endocrinol. (Copenh.) 92: 129, 1980.
Camanni F., Genazzani A.R., Massara F., De Leo V., Molinatti G.M., Muller E.E. Prolactin responsiveness to nomifensine in patients with hyperprolactinemia of tumorous or uncertain etiology. J. Clin. Endocrinol. Metab. 51: 650, 1980.
Kamoi K., Tchuchida I, Sato H., Tanaka R., Ishiguro T., Kaneko K., Iwasaki I., Shibata A. Comparison of the responses in the nomifensine test in patients with hyperprolactinemia due to prolactin-secreting pituitary tumors and non-prloactin-secreting hypothalamic tumors. J. Clin. Endocrinol. Metab. 53: 1285, 1981
Dallabonzana D., Spelta B., Botallo L., Oppizzi G., Silvestrini F., Chiodini P.G., Liuzzi A. Effects of nomifensine on growth hormone and prolactin secretion in normal subjects and in pathological hyperprolactinemia. J. Clin. Endocrinol. Metab. 54: 1125, 1982
Camanni F., Gennazzani A.R., De Leo V., Molinatti G.M., Campagnoli C., Cocchi D., Muller E.E. Effect of two indirectly acting dopamine agonists on prolactin secretion in normo- and hyperprolactinemic subjects: comparison with the effect of nomifensine. Neuroendocrinology 33: 300, 1981
De Leo V., Cella S.G., Camanni F., Gennazzani A.R., Muller E.E. Prolactin-lowering effect of amphetamine in normoprolactihemic subjects and in physiological and pathological hyperprolactinemia. Horm. Metab. Res. 15: 539, 1983.
Fine S.A., Frohman L.A. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors. J. Clin. Invest. 61: 973, 1978.
lanotta F., Fachinetti P., Fachinetti A., Pinotti G., Usellini L. Nomifensine, TRH and insulin-induced hypoglycaemia tests in the diagnosis of prolactinomas. J. Endocrinol. Invest. 6: 353, 1983.
Muller E.E., Cavagnini F., Martinez-Campos A., Mareschini C., Giovannini P., Novelli A., De Leo V. Dynamic testing of prolactin and growth hormone secretion in patients with neuroendocrine disorders. Acta Endocrinol. (Copenh.) 107: 155, 1984.
Casanueva F., Cocchi D., Locatelli V., Flauto C., Zambotti F., Bestetti G., Rossi G.L., Muller E.E. Defective central nervous system dopaminergic function in rats with estrogen-induced pituitary tumors, as assessed by plasma prolactin concentrations. Endocrinology: 110: 590, 1982.
Sarkar D.K., Gottschall P.E., Meites J. Decline of tuberoinfundibular dopaminergic function resulting from chronic hyperprolactinemia in rats. Endocrinology 115: 1269, 1984.
Bansal S., Lee L.A., Woolf P.D. Abnormal prolactin responsivity to dopaminergic suppression in hyperprolactinemic patients. Am. J. Med. 71: 961, 1981.
Serri O., Kuchel O., Bun N.T., Somma M. Differential effects of low dose dopamine infusion on prolactin secretion in normal and hyperprolactinemic subjects. J. Clin. Endocrinol. Metab. 56: 255, 1983.
Webb C.B., Thominet J.L., Barowsky H., Berelowitz M., Frohman L.A. Evidence for lactotroph dopamine resistence in idiopathic hyperprolactinemia. J. Clin. Endocrinol. Metab. 56: 1089, 1983.
Ramsdell J.S., Bethea C.L., Wilson C.B., Jaffe R.B., Weiner R.I. Dihydroergocryptine binding to human prolactin secreting adenomas. 63rd Ann. Meet. Endocr. Soc, 981, p. 202.
Cronin M.J., Cheung M.Y., Wilson C.B., Jaffe R.B., Weiner R.I. Tritiated spiperone binding to human anterior pituitaries and pituitary adenomas secreting prolactin growth homone and adrenocorticotropih. J. Clin. Endocrinol. Metab. 50: 387, 1980.
Bression D., Brendi A.M., Martres M.P., Nousbaum A., Cesselin F., Racadot J., Peilion F. Dopaminergic receptors in human prolactin-secreting pituitary adenomas: a quantitative study. J. Clin. Endocrinol. Metab. 51: 1037, 1980.
Martin M.C., Weiner R.I., Monroe S.E., Robert J.M., Licko V., Jaffa R.B. Prolactin secreting adenomas in women. VII Dopamine regulation of prolactin secretion. J. Clin. Endocrinol. Metab. 59: 485, 1984.
Ho K.Y., Smythe G.A., Duncan M., Lazarus L. Dopamine infusion studies in patients with pathological hyperprolactinemia: evidence for normal prolactin suppressibility but abnormal dopamine metabolism. J. Clin. Endocrinol. Metab. 58: 128, 1984.
Bethea C.L., Ramsdell J.S., Jaffe R.B., Wilson C.B., Weiner R.S. Characterization of dopaminergic regulation of human prolactin-secreting cells cultured on extracellar matrix. Endocrinology 108: 357, 1981.
Thorner M.O., Fluckiger E., Caine D.B. Bromocriptine therapy for hyperprolactinemia and suppression of puerperal lactation. In: Thorner M.O., Fluckiger E., Caine D.B. (Eds.), Bromocriptine: a clinical and pharmacological review. Raven Press, New York, 1980, p. 56.
Cowden E.H., Thompson J.A., Doyle D., Ratcliffe J.G., Mac Pherson P., Teasdale G.M. Tests of prolactin secretion in the diagnosis of prolactinomas. Lancet 1: 1155, 1979.
Massara F., Camanni F., Belforte L., Campagnoli C., Novi R.F., Molinatti G.M. Effects of sulpiride on plasma prolactin levels in women with puerperal or pathological hyperprolactinemia. Acta Endocrinol. (Copenh.) 95: 145, 1980.
Camanni F., Genazzani A.R., Massara F., La Rosa R., Cocchi D., Muller E.E. Prolactin releasing effect of domperidone in normoprolactinemic and hyperprolactinemic subjects. Neuroendocrinology, 30: 2, 1980.
Ho K.Y., Smythe G.A., Lazarus L. Prolactin response to dopamine synthesis inhibition using monoiodothyrosine in subjects on oral contraceptives and patients with pathological hyperprolactinemia. J. Clin. Endocrinol. Metab., 56: 692, 1983.
Ghigo E., Ciccarelli E., Novelli A., Massobrio M. Muller E.E., Camanni F. Prolactin and thyrotropin response to blockade of dopamine synthesis by monoidotyrosine in subjects with post-partum and pathological hyperprolactinemia. J. Endocrinol. Invest. 7: 525, 1985.
Ghigo E., Goffi S., Massara F. Prolactin and TSH response to alpha-methyl-l-tyrosine in normal subjects and in women with pathological hyperprolactinemia. Panminerva Medica 27: 21, 1985.
Gudelsky G.A., Porter J.C. Release of newly synthesized dopamine into hypophyseal portal vasculature of the rat. Neuroendocrinology 104: 583, 1979.
Reymond M.J., Porter J.C. Hypotalamic secretion of dopamine after inhibition of aromatic L-amino acid decarboxilase activity. Endocrinology111: 1051, 1982.
Demura R. Suda T., Wakabayashi T., Yoshimura M., Jibiki K., Odagiri E., Demura I., Shizume K. Plasma pituitary hormone response to the synthetic enkefaline analogue (FK 33–824) in normal subjects and patients with pituitary diseases. J. Clin. Endocrinol. Metab. 52: 263, 1981.
Reymond M.J., Kaur C., Porter J.C. An inhibitory role for morphine on the release of dopamine into hypophysial portal blood and on the synthesis of dopamine in tuberoinfundibular neurons. Brain Res, 262: 253, 1983.
Ghigo E., Goffi S., Molinatti G.M., Camanni F., Massara F. Prolactin and TSH response to both domperidone and TRH in normal and hyperprolactinemic women after dopamine synthesis blockade. Clin. Endocrinol. (Oxf.) 23: 155, 1985.
Crosignani P.G., Reschini E., Peracchi M., Lombroso G.C., Mattei A., Caccamo A. Failure of dopamine infusion to suppress the plasma prolactin response to sulpiride in normal and hyperprolactinemic subjects. J. Clin. Endocrinol. Metab. 45: 841, 1977.
Quigley M.E., Judd S.J., Gilliland G.B., Yen S.S.C. Functional studies of dopamine control of prolactin secretion in normal women and women with hyperprolactinemic pituitary microadenoma. J. Clin. Endocrinol. Metab. 50: 994, 1980.
Ferrari C., Rampini P., Benco R., Caldara R., Scarduelli C., Crosignani P.G. Functional characterization of hypothalamic hyperprolactinemia. J. Clin. Endocrinol. Metab. 55: 987, 1982.
Genazzani A.R., Lancranjan I., Picciolini E., La Rosa E., Audibert A. Evidence for central alpha-adrenergic inhibitory control of plasma prolactin. In: Abstract book Int. Symposium “Growth hormome and other biologically active peptides”. Ricerca Scientifica ed Educazione Permanente Suppl. 11, p.81 (Abstr.).
Reichlin S., Molitch M. Neuroendocrine aspects of pituitary adenoma. In: Camanni F., Muller E.E. (Eds.), Pituitary hyperfunction. Raven Press, New York, 1984, p. 47.
Kaji H., Chihara K. Kita T., Kashio Y., Okimura Y., Fujita T. Lack of plasma prolactin response to intravenously injected vasoactive intestinal polypeptide in patients with prolactin-secreting adenoma. Acta Endocrinol. (Copenh.) 110: 445, 1985.
Le Dafniet M., Brandi M., Bression D., Racadot T., Peilion F. Evidence of receptors for thyrotropin-releasing hormone in human prolactin-secreting adenomas. J. Clin. Endocrinol. Metab. 57: 425, 1983.
Nicosia S., Spada A., Borghi C., Cortellazzi L., Giannattasio G. Effects of vasoactive intestinal polypeptide adenomas. Stimulations of PRL release and activation of adenilate cyclase. FEBS Lett. 112: 159, 1980.
Swearinger K.C., Nicoll C. Prolactin turnover in rat adenohypophysis in vivo: its evaluation as a method for estimating secretion rates. J. Endocrinol. 53: 1, 1972.
Knew-Hsiung L., Amenomori Y., Chiao-Ling C., Mettes J. Effects of central acting drugs on serum and pituitary prolactin levels in rats. Endocrinology 87: 667, 1987.
Jenkins J.S., Gilbert C.J., Ang V. Hypothalamic-pituitary function in patients with craniopharyngiomas. J. Clin. Endocrinol. Metab. 43: 394, 1976.
Kapcala M.T., Molitch M.E., Post K.T., Miller B.J., Jackson J.M.D., Reichlin S. Galctorrhea, oligo-amenorrhea and hypeprolactinemia in patients with craniopharyngioma. J. Clin. Endocrinol. Metab. 53: 798, 1980.
Shas R.P., Leavens M.E., Samaan N.A. Galctorrhea, amenorrhea and hyperprolactinemia as manifestations of parasellar meningioma. Arch. Intern. Med. 140: 1608, 1980.
Kljin J.G.M., Lamberts S.W.J., De Jong F.H., Birkenhager J.C. The value of thyrotropin-releasing hormone test in patients with prolactin-secreting pituitary tumors and suprasellar non pituitary tumors. Fertil. Steril, 35: 155, 1981.
Healy D.L., Burger H.G. Sustained elevation of serum prolactin by metoclopramide: a clinical model of idiopathic hyperprolactinemia. J. Clin. Endocrinol. Metab. 46: 709, 1978.
Nicoletti I., Filipponi P., Fedeli L., Sgrappini M., Gregorini G., Ambrosi F., Santeusanio F. Catecholamines and pituitary function. III. Restoration of the prolactin response to thyrotropin-releasing hormone by low dose dopamine infusion in women with pathological hyperprolactinemia. Horm. Res. 20: 202, 1984.
Tater D., Charpentier G., Besson G., Rosselin G., Bercovici J.P. Le VIP lève l’inhibition de la secretion de prolactine induite par la dopamine chezles sujets presentant un prolactinome. C.R. Acad. Sci. 297: 331, 1983.
Camanni F., Massara F. L’iperprolattinemia. Fisopatologia, clinica e terapia. Masson Italia Editori, Milano, 1987.
Ghigo E., Ciccarelli E., Bianchi S.D., Gatti G., Molinatti G.M., Massara F., Muller E.E., Camanni F. Comparison of computed tomographic findings with tests of hypothalamo-pituitary function in 72 patients with hyperprolactinemia. Acta Endocrinol. (Copenh.) 112: 20, 1986.
Ciccarelli E., Ghigo E., Mazza E., Gandini G., Avataneo T., Rizzi G., Bertagna A., Camanni F. Pituitary computed tomography and dynamic tests of prolactin and thyrotropin secretion in 103 hyperprolactinemic patients. Panminerva Medica 29: 195, 1987.
Scanion M.F., Weightman D.R., Maza B., Heath M., Shale D.J., Snow M.H., Hall R. Evidence for dopaminergic control of thyrotropin release in man. Lancet 2: 421, 1977.
Seki K., Uesato T., Kato K. Effects of dopamine antagonist (metoclopramide) on the release of the adenohypophyseal hormones in amenorrhoeic patients with and without hyperprolactinemia. Acta Endocrinol. (Copenh.) 101: 166, 1982.
Ho K.Y., Smythe G.A., Lazarus L. Enhanced hypothalamic inhibition of LH, TSH and GH release in patients with pathological hyperprolactinemia. Acta Endocrinol. (Copenh.) 108: 289, 1985.
Spitz I.M, Hoas M., Trestian S., Zylber-Haran E., Shilo S. The interrelationship between prolactin and thyrotropin secretion following dopaminergic blockage in patients with mild hyperprolactinemia and without any demonstrable pituitary tumor. Clin. Endocrinol. (Oxf.) 19: 285, 1983.
Moore K.E., Demarest K.T., Johnston C.A. Influence of prolactin on dopaminergic neuronal systems in the hypothalamus. Fed. Proc. 39: 2912, 1980.
Faglia G., Spada A., Moriondo P., Giannattasio G., Nissim E., Elli R. What is the role of dopamine in the pathogenesis of prolactinomas? In: Camanni F., Muller E.E. (Eds.), Pituitary hyperfunction. Physiopathology and clinical aspects. Raven Press, New York, 1984, p. 279.
Camanni F., Ghigo E., Ciccarelli E., Massara F., Campagnoli C., Molinatti G.M., Muller E.E. Defective regulation of prolactin secretion after successful removal of prolactinomas. J. Clin. Endocrinol. Metab., 57: 1270, 1983.
Camanni F., Ghigo E., Ciccarelli E., Savino L. Miola C., Bertagna A. Long-term follow-up of prolactinoma patients successfully cured by adenomectomy. In: A.R. Genazzani, U. Montemagno, C. Nappi, F. Petraglia (Eds.), The brain and female reproductive function. Parthenon Publ. Press, Casterton Hall, Carnforth, p. 561, 1987.
Erfurth E.M., Hedner P., Nilsson A. Basal and THR stimulated serum levels of TSH in patients with hyperprolactinaemia and in subjects on oestrogens treatment. Acta Endocrinol. (Copenh.) 102: 173, 1983.
Rodriguez-Arnao M.D, Peters J.R., Foord S.M., Dieguez C., Edwards C., Gomez-Pan A., Hall R. Newcombe R.G., Scanion M.F. Exaggerated circadian variation in basal thyrotropin (TSH) and in dopaminergic inhibition of TSH release in pathological hyperprolactinemia: evidence against a hypothalamic dopaminergic defect. J. Clin. Endocrinol. Metab., 57: 975, 1983.
Nicoletti I., Filipponi P., Fedeli L., Ambrosi F., Gianmartino P., Spinozzi F., Santeusanio F. Cathecolamines and pituitary function. IV. Effects of low-dose dopamine infusion and long-term bromocriptine treatment on the abnormal thyrotroph (TSH) dynamics in patients with pathological hyperprolactinemia. Acta Endocrinol. (Copenh.) 11: 154, 1986.
Schlechte J.A., Sherman B.M., Chapler F.K., von-Gilder J. Long-term follow-up of women with surgically treated prolactin-secreting pituitary tumors. J. Clin. Endocrinol. Metab., 62: 1296, 1986.
Schlechte J.A., Sherman B. Abnormal regulation of prolactin secretion after successful surgery for prolactin secreting pituitary tumors. Clin. Endocrinol. (Oxf.) 15: 165, 1981.
Frohman L.A., Berlowitz M., Gonzales C., Borowski H., Rao R., Lim V.S., Frohman M.A., Thominet J.L. Studies of dopaminergic mechanisms in hyperprolactinemic states. In: Crosignani P.G., Rubin B.L. (Eds.), Endocrinology of human infertility: new aspects. Academic Press, London, 1981, p. 39.
Jaquet P. Grisoli F., Guibut M., Lissitzky J.C., Carajon P. Prolactin secreting tumors: endocrine status before and after surgery in 33 women. J. Clin. Endocrinol. Metab. 46: 459, 1978.
Murray F., Ostermans J., Sulewsy J., Page R., Bergland R., Hammonds J. Pituitary function following surgery for prolactinomas. Obstet. Gynecol. 54: 65, 1979.
Barbarino A., De Marinis L., Menini E., Anile C., Maira G. Prolactin-secreting pituitary adenomas: prolactin dynamics before and after transsphenoidal surgery. Acta Endocrinol. (Copenh.) 91: 397, 1979.
Molitch M.E., Goodman R.H., Post K.D., Biller B.J., Moses A.C., King L.W., Feldman Z.T., Reichlin S. Surgical cure of prolactinoma reverses abnormal prolactin response to carbidopa/L-dopa. J. Clin. Endocrinol. Metab., 55: 1118, 1982.
Arafah B.M., Brodkey J.S., Pearson O.H. Gradual recovery of lactotroph responsiveness to dynamic stimulation following surgical removal of prolactinomas: long-term follow-up studies. Metabolism 35: 905, 1986.
Fuxe K. Brain catecholamine neurons as regulators of prolactin secretion and as a target for prolactin action. In Poceedings of the third International Meeting on Human Prolactin. Athens, Raven Press, New York, 1982.
Reymond M.J., Speciale S.G., Porter J.C. Dopamine in plasma of lateral and medial hypophysial portal vessels: evidence for regional variation in the release of hypothalamic dopamine into hypophysial portal blood. Endocrinology 112: 1958, 1983.
Weiner R.I., Elias K.A., Monnet F. The role of vascular changes in the etiology of prolactin secreting pituitary tumors. In: Mac Leod R.M., Thorner M.O., Scapagnini V. (Eds.), Prolactin: basic and clinical correlates. Liviana Press, Padova, Fidia Research. Series, 1985, vol. 1, p. 641.
Erroi A., Bassetti M., Spada A., Giannattasio G. Microvasculature of human micro- and macroadenomas. A morphological study. Neuroendocrinology 43: 159, 1986.
Sherman B.M., Wallace R.B., Chapler F.K., Luciano A.A., Bean J.A. In: Camanni F., Muller E.E. (Eds.), Pituitary hyper-function. Physiopathology and clinical aspects. Raven Press, New York, 1984, p. 167.
Costello R.T. Subclinical adenomas of the pituitary gland. Am. J. Pathol. 12: 205, 1983.
Burrow G.N., Wortzmann G., Rewcastle N.B., Holtgate R.C., Kovacs K. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N. Engl. J. Med. 304: 156, 1981.
Harris P.E., Valcavi R., Artioli C., Casioli P., Foord S.M., Dieguez C., Peters J.R., Hall R., Scanion M.F. The influence of oestrogens on the sensitivity of prolactin, TSH and LH to the inhibitory action of dopamine in hyperprolactinemic patients. In: Mac Leod R.M., Thorner M.O., Scapagnini U. (Eds.), Prolactin. Basic and clinical correlates. Liviana Press, Padova, Fidia Research. Series, 1985, vol. 1, p. 753.
Demarest K.T., Mc Kay, Riegle G.D., Moore K.I. Biochemical indexes of tuberoinfudibular dopaminergic neuronal activities during lactation: a lack of response to prolactin. Neuroendocrinology 36: 130, 1983.
Ghigo E., Pogliano G.F., Campagnoli C., Bertagna A., Camanni F., Massara F. Estrogenic treatment does not modify the PRL and TSH responses to domperidone and TRH in patients with tumoral hyperprolactinemia. J. Endocrinol. Invest. 7: 525, 1984.
Schlechte H., Sherman B., Halmi N., van Gilder J., Chapler F., Dolan K., Granner D., Duello T., Harris C. Prolactin-secreting pituitary tumors in amenorrheic women. A comprehensive study. Endocr. Rev. 1: 295, 1980.
Massara F., Genazzani A.R., Camanni F., DeLeo V., Molinatti G.M., Muller E.E. Tests of prolactin secretion in the diagnosis of hyperprolactinemic states: nomifensine and domperidone. Fertil. Steril. 35: 149, 1981.
Pontiroli A.E., Falsetti L., Voltolini A.M., Albertetto M., Pellicciotta G., De Pasqua A., Girardi A.M., Pozza G. Benserazide, a stimulator of prolactin release: a new test in the diagnosis of pituitary prolactin secreting tumors. Acta Endocrinol. (Copenh.) 98: 326, 1981.
Pontiroli A.E., Loda G., Roggia A., Scagliolo P., Falsetti L. Benserazide and nomifensine in the diagnosis of prolactin-secreting pituitary adenomas. Acta Endocrinol. (Copenh.) 101: 171, 1982.
Iodice I, Lombardi G., Tommaselli A., Rossi R., Annunziata L., Minozzi M. Agreement of prolactin response to Cimetidine and nomifensine in patients with prolactin-secreting tumors and idiopathic hyperprolactinemia. Neuroendocrinology 35: 333, 1982.
Ferrari C., Crosignani P.G., Caldara R., Picciotti M.C., Malinverni A., Barattini G., Rampini P., Telloli P. Failure of nomifensine administration to discriminate between tumorous and nontumorous hyperprolactinemias. J. Clin. Endocrinol. Metab. 50: 23, 1980.
Moriondo P., Travaglini P., Nissim M., Faglia G. Evaluation of two inhibitory tests (nomifensine and L-dopa Carbidopa) for the diagnosis of hyperprolactinemic states. Clin. Endocrinol. (Oxf.) 13: 525, 1980.
Abboud C.F., Lows E.R. Diagnosis of pituitary tumours. Endocrinol. Metab. Clin. North Am. 17: 241, 1988.
Balagura S., Frantz A.G., Housepian E.M. Carmel P.W. The specificity of serum prolactin as a diagnostic indicator of pituitary adenoma. J. Neurosurg. 51: 42, 1979.
Sklar G.A., Grumbach M.M., Koplan S.L., Conte F.A. Hormonal and metabolic abnormalities associated with central nervous system germinoma in children and adolescent and the effect of the therapy: report of 10 patients. J. Clin. Endocrinol. Metab. 52: 9, 1981.
Lundberg P.O., Osterman P.D., Wide L. Serum prolactin in patients with hypothalamus and pituitary disorders. J. Neurosurg. 55: 194, 1981.
Ferrari C., Rampini P., Benco R., Caldara R., Scarduelli C., Crosignani P.G. Functional characterization of hypothalamic hyperprolactinemia. J. Clin. Endocrinol. Metab. 55: 897, 1982.
Scanion M.F., Peters J.R., Salvador J., Richards S.H., John R., Howell S., Williams E.D., Thomas J.P., Hall R. The preoperative and postoperative investigation of TSH and prolactin release in the management of patients with hyperprolactinemia due to prolactinomas and nonfunctional pituitary tumours: relationship to adenoma size at surgery. Clin. Endocrinol. (Oxf.) 24: 435, 1986.
Ciccarelli E., Ghigo E., Savino L., Miola C., Camanni F. Letter to Editor. Clin. Endocrinol. (Oxf,) 25: 749, 1986.
Randall R.V., Scheithauer R.W., Laws E.R., Abboud C.F., Ebersold M.J., Kao P.C. Pituitary adenomas associated with hyperprolactinemia: a clinical and immunohistochemical study on 97 patients operated on transsphenoidally. Mayo Clin. Proc. 60: 753, 1985.
Molitch M.E., Reichlin S. Hypothalamic hyperprolactinemia: neuroendocrine regulation of prolactin secretion in patients with lesions of the hypothalamus and pituitary stalk. In: Mac Leod R.M., Thorner M.O., Scapagnini U. (Eds.), Prolactin. Basic and clinical correlates. Liviana Press, Padova, Fidia Research. Series, 1985, vol. 1, p. 709.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Camanni, F., Ciccarelli, E., Ghigo, E. et al. Hyperprolactinemia: neuroendocrine and diagnostic aspects. J Endocrinol Invest 12, 653–668 (1989). https://doi.org/10.1007/BF03350030
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03350030